Sonmez Kenan, Drenser Kimberly A, Capone Antonio, Trese Michael T
Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.
Ophthalmology. 2008 Jun;115(6):1065-1070.e1. doi: 10.1016/j.ophtha.2007.08.050. Epub 2007 Nov 26.
To understand better the role of vascular endothelial growth factor (VEGF) and stromal cell-derived factor 1alpha (SDF-1alpha) in the pathogenesis of retinopathy of prematurity (ROP).
Experimental study.
The study group consisted of 22 eyes with stage 4 ROP (12 vascularly active, 10 vascularly inactive), from which vitreous samples were obtained. Vitreous samples from 5 eyes undergoing surgery for congenital cataract were used as controls.
The vitreous samples were analyzed for concentrations of total protein, VEGF, and SDF-1alpha. Vascular activity was graded at the time of surgery and was defined as the presence of plus disease, neovascularization growing onto the vitreous at the ridge or tractional detachment area, or combined effusive and tractional retinal detachment.
Vitreous concentrations of VEGF and SDF-1alpha were compared among vascularly active stage 4 ROP eyes, vascularly inactive stage 4 ROP eyes, and control eyes.
Vitreous concentrations of VEGF and SDF-1alpha were elevated in eyes with ROP compared with control eyes. The median VEGF level was 59 pg/ml (range, 38-135 pg/ml) in the control group, 316 pg/ml (range, 105-665 pg/ml) in the vascularly inactive ROP group, and 3454 pg/ml (range, 774-8882 pg/ml) in the vascularly active ROP group. The median SDF-1alpha level was 327 pg/ml (range, 299-393 pg/ml) in the control group, 609 pg/ml (range, 515-1116 pg/ml) in the vascularly inactive ROP group, and 1029 pg/ml (range, 807-3015 pg/ml) in the vascularly active ROP group. The differences in both vitreous VEGF and SDF-1alpha concentrations between the three groups were statistically significant (P<0.001 and P<0.001, respectively). The eyes graded as vascularly active at the time of surgery demonstrated the highest vitreous levels of both VEGF and SDF-1alpha, and these levels were statistically significant when compared with vascularly inactive eyes (P<0.001 and P = 0.001, respectively) and control eyes (P = 0.001 and P = 0.001, respectively).
These findings confirm the increase in vitreous VEGF and SDF-1alpha levels in eyes with vascularly active stage 4 ROP. Anti-VEGF treatment may be of benefit in some eyes that develop ROP.
为了更好地理解血管内皮生长因子（VEGF）和基质细胞衍生因子1α（SDF - 1α）在早产儿视网膜病变（ROP）发病机制中的作用。
实验研究。
研究组由22只患有4期ROP的眼睛组成（12只血管活跃型，10只血管非活跃型），从中获取玻璃体样本。5只接受先天性白内障手术的眼睛的玻璃体样本用作对照。
分析玻璃体样本中的总蛋白、VEGF和SDF - 1α浓度。手术时对血管活性进行分级，定义为存在增值性病变、新生血管长入玻璃体嵴或牵拉性视网膜脱离区域，或合并渗出性和牵拉性视网膜脱离。
比较血管活跃型4期ROP眼、血管非活跃型4期ROP眼和对照眼中VEGF和SDF - 1α的玻璃体浓度。
与对照眼相比，ROP眼中VEGF和SDF - 1α的玻璃体浓度升高。对照组中VEGF的中位数水平为59 pg/ml（范围38 - 135 pg/ml），血管非活跃型ROP组为316 pg/ml（范围105 - 665 pg/ml），血管活跃型ROP组为3454 pg/ml（范围774 - 8882 pg/ml）。对照组中SDF - 1α的中位数水平为327 pg/ml（范围299 - 393 pg/ml），血管非活跃型ROP组为609 pg/ml（范围515 - 1116 pg/ml），血管活跃型ROP组为1029 pg/ml（范围807 - 3015 pg/ml）。三组之间玻璃体VEGF和SDF - 1α浓度的差异均具有统计学意义（分别为P<0.001和P<0.001）。手术时分级为血管活跃型的眼睛显示VEGF和SDF - 1α的玻璃体水平最高，与血管非活跃型眼睛（分别为P<0.001和P = 0.001）及对照眼睛（分别为P = 0.001和P = 0.001）相比，这些水平具有统计学意义。
这些发现证实了血管活跃型4期ROP眼中玻璃体VEGF和SDF - 1α水平升高。抗VEGF治疗可能对一些发生ROP的眼睛有益。
